Proficio Capital Partners LLC Acquires Shares of 46,780 Masimo Co. (NASDAQ:MASI)

Proficio Capital Partners LLC acquired a new position in Masimo Co. (NASDAQ:MASI - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 46,780 shares of the medical equipment provider's stock, valued at approximately $7,733,000. Proficio Capital Partners LLC owned approximately 0.09% of Masimo at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. FMR LLC boosted its stake in shares of Masimo by 41.2% during the 3rd quarter. FMR LLC now owns 6,756,618 shares of the medical equipment provider's stock worth $900,860,000 after acquiring an additional 1,970,883 shares in the last quarter. State Street Corp lifted its holdings in Masimo by 0.7% in the 3rd quarter. State Street Corp now owns 1,438,814 shares of the medical equipment provider's stock worth $191,837,000 after purchasing an additional 10,179 shares during the last quarter. Westfield Capital Management Co. LP boosted its position in Masimo by 23.2% during the third quarter. Westfield Capital Management Co. LP now owns 1,394,056 shares of the medical equipment provider's stock worth $185,869,000 after purchasing an additional 262,370 shares during the period. Geode Capital Management LLC grew its holdings in Masimo by 1.5% during the third quarter. Geode Capital Management LLC now owns 792,886 shares of the medical equipment provider's stock valued at $105,741,000 after purchasing an additional 11,984 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA raised its position in shares of Masimo by 9.8% in the third quarter. Massachusetts Financial Services Co. MA now owns 792,166 shares of the medical equipment provider's stock valued at $105,619,000 after purchasing an additional 70,440 shares during the period. 85.96% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Analyst Ratings Changes

Several research firms recently issued reports on MASI. Needham & Company LLC reaffirmed a "hold" rating on shares of Masimo in a report on Wednesday, February 26th. Raymond James upped their price target on shares of Masimo from $170.00 to $194.00 and gave the company an "outperform" rating in a report on Friday, December 27th. Wells Fargo & Company lifted their price objective on Masimo from $193.00 to $205.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. Piper Sandler boosted their price objective on Masimo from $210.00 to $215.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Finally, Stifel Nicolaus reaffirmed a "buy" rating and issued a $190.00 target price (up previously from $170.00) on shares of Masimo in a report on Friday, November 22nd. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $194.80.

Masimo Stock Performance

Shares of NASDAQ MASI traded down $9.12 during mid-day trading on Thursday, hitting $177.07. The company had a trading volume of 176,535 shares, compared to its average volume of 620,134. Masimo Co. has a 12 month low of $101.61 and a 12 month high of $194.88. The firm has a market cap of $9.55 billion, a P/E ratio of 122.47 and a beta of 1.02. The business's 50-day simple moving average is $174.79 and its 200-day simple moving average is $155.27. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11.

Masimo (NASDAQ:MASI - Get Free Report) last announced its quarterly earnings data on Tuesday, February 25th. The medical equipment provider reported $1.80 EPS for the quarter, topping analysts' consensus estimates of $1.42 by $0.38. The company had revenue of $600.70 million during the quarter, compared to the consensus estimate of $593.35 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. As a group, analysts predict that Masimo Co. will post 4.1 earnings per share for the current fiscal year.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.